Assay Detail
Binding
CHEMBL4307050
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Inhibition of VEGFR2 (unknown origin)
8
Total Activities
8
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Binding |
| Organism | Homo sapiens |
| Confidence | 9 — Direct single protein target |
| Curated By | Autocuration |
Target
Vascular endothelial growth factor receptor 2 (CHEMBL279) ↗| Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
Publication
Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 8 | 8.36 | 10.46 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL2105717 | CABOZANTINIB | 4.0 | 1 | 10.46 |
| CHEMBL1289926 | AXITINIB | 4.0 | 1 | 9.74 |
| CHEMBL1289601 | LENVATINIB | 4.0 | 1 | 8.40 |
| CHEMBL1946170 | REGORAFENIB | 4.0 | 1 | 8.38 |
| CHEMBL502835 | NINTEDANIB | 4.0 | 1 | 7.89 |
| CHEMBL477772 | PAZOPANIB | 4.0 | 1 | 7.52 |
| CHEMBL24828 | VANDETANIB | 4.0 | 1 | 7.40 |
| CHEMBL535 | SUNITINIB | 4.0 | 1 | 7.10 |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL2105717 | CABOZANTINIB | IC50 | = | 0.035 | nM | 10.46 |
| CHEMBL1289926 | AXITINIB | IC50 | = | 0.18 | nM | 9.74 |
| CHEMBL1289601 | LENVATINIB | IC50 | = | 4.0 | nM | 8.40 |
| CHEMBL1946170 | REGORAFENIB | IC50 | = | 4.2 | nM | 8.38 |
| CHEMBL502835 | NINTEDANIB | IC50 | = | 13.0 | nM | 7.89 |
| CHEMBL477772 | PAZOPANIB | IC50 | = | 30.0 | nM | 7.52 |
| CHEMBL24828 | VANDETANIB | IC50 | = | 40.0 | nM | 7.40 |
| CHEMBL535 | SUNITINIB | IC50 | = | 80.0 | nM | 7.10 |